Enhancing drug-drug Interaction Prediction by Integrating Physiologically-Based Pharmacokinetic Model with Fraction Metabolized by CYP3A4

被引:2
|
作者
Jiang, Pin [1 ]
Chen, Tao [2 ]
Chu, Lin-Feng [1 ]
Xu, Ren-Peng [1 ]
Gao, Jin-Ting [3 ]
Wang, Li [3 ]
Liu, Qiang [3 ]
Tang, Lily [3 ]
Wan, Hong [1 ]
Li, Ming [4 ]
Ren, Hong-Can [3 ]
机构
[1] Shanghai Medicilon Inc, Dept DMPK, 585 Chuanda Rd, Shanghai 201299, Peoples R China
[2] Shanghai PharmoGo Co Ltd, Shanghai, Peoples R China
[3] GenFleet Therapeut Shanghai Inc, Drug Discovery Dept, 1206 Zhangjiang Rd, Suite A, Shanghai 201203, Peoples R China
[4] Zhengzhou Univ, Dept Cardiovasc Surg, Affiliated Hosp 1, 1 Jianshe Rd, Zhengzhou 450000, Peoples R China
关键词
Drug-drug interaction; PBPK; fraction metabolized; CYP inhibition;
D O I
10.1080/17425255.2023.2263358
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Enhancing the precision of drug-drug interaction (DDI) prediction is essential for improving drug safety and efficacy. The aim is to identify the most effective fraction metabolized by CY3A4 (fm) for improving DDI prediction using physiologically based pharmacokinetic (PBPK) models.Research Design and Methods: The fm values were determined for 33 approved drugs using a human liver microsome for in vitro measurements and the ADMET Predictor software for in silico predictions. Subsequently, these fm values were integrated into PBPK models using the GastroPlus platform. The PBPK models, combined with a ketoconazole model, were utilized to predict AUCR (AUCcombo with ketoconazole/AUCdosing alone), and the accuracy of these predictions was evaluated by comparison with observed AUCR.Results: The integration of in vitro fm method demonstrates superior performance compared to the in silico fm method and fm of 100% method. Under the Guest-limits criteria, the integration of in vitro fm achieves an accuracy of 76%, while the in silico fm and fm of 100% methods achieve accuracies of 67% and 58%, respectively.Conclusions: Our study highlights the importance of in vitro fm data to improve the accuracy of predicting DDIs and demonstrates the promising potential of in silico fm in predicting DDIs.
引用
收藏
页码:721 / 731
页数:11
相关论文
共 50 条
  • [41] Application of Physiologically-Based Pharmacokinetic Modeling to Predict Gastric pH-Dependent Drug-Drug Interactions for Weak Base Drugs
    Dong, Zhongqi
    Li, Jia
    Wu, Fang
    Zhao, Ping
    Lee, Sue-Chih
    Zhang, Lillian
    Seo, Paul
    Zhang, Lei
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2020, 9 (08): : 456 - 465
  • [42] Prediction of pharmacokinetics and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach: A case study of caffeine and ciprofloxacin
    Park, Min-Ho
    Shin, Seok-Ho
    Byeon, Jin-Ju
    Lee, Gwan-Ho
    Yu, Byung-Yong
    Shin, Young G.
    KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY, 2017, 21 (01) : 107 - 115
  • [43] Does the choice of applied physiologically-based pharmacokinetics platform matter? A case study on simvastatin disposition and drug-drug interaction
    Garcia, Luna Prieto
    Lundahl, Anna
    Ahlstrom, Christine
    Vildhede, Anna
    Lennernas, Hans
    Sjogren, Erik
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2022, 11 (09): : 1194 - 1209
  • [44] Utility of CYP3A4 and PXR-CAR-CYP3A4/3A7 Transgenic Mouse Models To Assess the Magnitude of CYP3A4 Mediated Drug-Drug Interactions
    Ly, Justin Q.
    Messick, Kirsten
    Qin, Ann
    Takahashi, Ryan H.
    Choo, Edna F.
    MOLECULAR PHARMACEUTICS, 2017, 14 (05) : 1754 - 1759
  • [45] Physiologically Based Pharmacokinetic Modeling Characterizes the Drug-Drug Interaction Between Saxagliptin and Rifampicin in Patients With Renal Impairment
    Wu, Wanhong
    Lin, Rongfang
    Ke, Meng
    Ye, Lingling
    Lin, Cuihong
    JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 63 (07) : 848 - 858
  • [46] Assessment of cytochrome P450 3A4-mediated drug-drug interactions for ipatasertib using a fit-for-purpose physiologically based pharmacokinetic model
    Jing, Jing
    Chen, Yuan
    Musib, Luna
    Jin, Jin Y.
    Cheung, Kit Wun Kathy
    Yoshida, Kenta
    Sane, Rucha
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 89 (05) : 707 - 720
  • [47] Evaluation of Drug-Drug Interaction Potential Between Sacubitril/Valsartan (LCZ696) and Statins Using a Physiologically Based Pharmacokinetic Model
    Lin, Wen
    Ji, Tao
    Einolf, Heidi
    Ayalasomayajula, Surya
    Lin, Tsu-Han
    Hanna, Imad
    Heimbach, Tycho
    Breen, Christopher
    Jarugula, Venkateswar
    He, Handan
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2017, 106 (05) : 1439 - 1451
  • [48] Predicting Drug-Drug Interactions Involving the Inhibition of Intestinal CYP3A4 and P-Glycoprotein
    Tachibana, Tatsuhiko
    Kato, Motohiro
    Takano, Junichi
    Sugiyama, Yuichi
    CURRENT DRUG METABOLISM, 2010, 11 (09) : 762 - 777
  • [49] Molecular docking to understand the metabolic behavior of GNF-351 by CYP3A4 and its potential drug-drug interaction with ketoconazole
    Liu, Tao
    Qian, Ge
    Wang, WenTing
    Zhang, YanGuo
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2015, 40 (02) : 235 - 238
  • [50] Prediction of CYP-Mediated Drug Interaction Using Physiologically Based Pharmacokinetic Modeling: A Case Study of Salbutamol and Fluvoxamine
    Marques, Lara
    Vale, Nuno
    PHARMACEUTICS, 2023, 15 (06)